Ultragenyx Pharmaceutical Independent Director Matthew Fust Sells 45% Of Holding
Ultragenyx Pharmaceutical Independent Director Matthew Fust Sells 45% Of Holding
Some Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shareholders may be a little concerned to see that the Independent Director, Matthew Fust, recently sold a substantial US$620k worth of stock at a price of US$50.88 per share. That's a big disposal, and it decreased their holding size by 45%, which is notable but not too bad.
獨立董事馬修·福斯特最近以每股50.88美元的價格出售了價值62萬美元的大量股票,一些Ultragenyx Pharmaceutical Inc.(納斯達克股票代碼:RARE)的股東可能會有點擔心。這是一筆巨額出售,它使他們的持股規模減少了45%,這值得注意,但還不錯。
The Last 12 Months Of Insider Transactions At Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical 過去 12 個月的內幕交易
Notably, that recent sale by Matthew Fust is the biggest insider sale of Ultragenyx Pharmaceutical shares that we've seen in the last year. So we know that an insider sold shares at around the present share price of US$47.66. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. In this case, the big sale took place at around the current price, so it's not too bad (but it's still not a positive).
值得注意的是,馬修·富斯特最近的出售是我們去年對Ultragenyx Pharmaceutical股票的最大一次內幕出售。因此,我們知道一位內部人士以目前的47.66美元左右的股價出售了股票。儘管內幕拋售是負面的,但對我們來說,如果以較低的價格出售股票,則負面影響更大。在這種情況下,大甩賣是在當前價格左右進行的,因此還不錯(但仍然不是積極的)。
Insiders in Ultragenyx Pharmaceutical didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
去年,Ultragenyx Pharmaceutical的內部人士沒有購買任何股票。你可以在下面看到過去 12 個月內幕交易(公司和個人)的直觀描述。如果你想確切地知道誰賣了、賣了多少以及何時出售,只需點擊下圖!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240313/0-4575b9c770cabc9d7b0b2d96460cdeeb-0-1f23fbf8e66cbe009ade7db5d3eb58fe.png/big)
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
對於那些喜歡尋找中獎投資的人來說,這份最近有內幕收購的成長型公司的免費名單可能只是門票。
Does Ultragenyx Pharmaceutical Boast High Insider Ownership?
Ultragenyx Pharmaceutical 是否擁有很高的內部所有權?
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. Ultragenyx Pharmaceutical insiders own 3.9% of the company, currently worth about US$155m based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
查看公司的內部持股總量可以幫助你了解他們是否與普通股股東保持一致。我們通常希望看到相當高的內部所有權水平。Ultragenyx製藥內部人士擁有該公司3.9%的股份,根據最近的股價,目前價值約1.55億美元。我喜歡看到這種程度的內部所有權,因爲它增加了管理層考慮股東最大利益的機會。
So What Does This Data Suggest About Ultragenyx Pharmaceutical Insiders?
那麼這些數據對Ultragenyx製藥業內部人士有什麼啓示呢?
Insiders sold stock recently, but they haven't been buying. Looking to the last twelve months, our data doesn't show any insider buying. It is good to see high insider ownership, but the insider selling leaves us cautious. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. In terms of investment risks, we've identified 3 warning signs with Ultragenyx Pharmaceutical and understanding them should be part of your investment process.
內部人士最近出售了股票,但他們一直沒有買入。展望過去的十二個月,我們的數據並未顯示任何內幕買盤。看到較高的內部所有權是件好事,但內幕拋售使我們持謹慎態度。因此,雖然了解內部人士在買入或賣出方面的所作所爲很有幫助,但了解特定公司面臨的風險也很有幫助。在投資風險方面,我們已經確定了Ultragenyx Pharmaceutical的3個警告信號,並了解它們應該成爲您投資過程的一部分。
Of course Ultragenyx Pharmaceutical may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
當然,Ultragenyx Pharmaceutical可能不是最好的買入股票。因此,您可能希望看到這個免費的高質量公司集合。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。